Aroda VR, Faurby M, Lophaven S, et al
Semaglutide constipation and tirzepatide constipation are among the most commonly reported side effects, and they deserve targeted management rather than passive tolerance
their association with SGLT-2 inhibitors requires further confirmation through large, randomized trials ( SGLT2 inhibitors should be discontinued in specific clinical scenarios to mitigate potential adverse events
Coordinating with manufacturers for patient assistance programs: HSSPs can connect patients with financial assistance resources to lower out-of-pocket costs
Mechanistically, we show that this effect occurs independently of canonical melatonin receptor signaling in ILC2s and instead requires activation of the NRF2-glutathione axis
This helps put the safety of semaglutide into perspective for the donation process